ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences completed its acquisition of the entire stake in Actis Generics Private Limited, making it a subsidiary of the company.
RPG Life Sciences clarified that the recent increase in its trading volume is attributable to market conditions and there is no undisclosed price-sensitive information.
RPG Life Sciences completed the slump sale of its API and intermediates business to Raghava Life Sciences Private Limited, effective September 16, 2026.
RPG Life Sciences' subsidiary, RPG Active Pharma, allotted shares to India Life Sciences Fund and Vistaject Fund for ₹243.33 crores. Post-allotment, RPG Active Pharma remains a subsidiary.
RPG Life Sciences announced a strategic reorganization of its API business into a new subsidiary, RPGAP, involving a PE partnership and two bolt-on acquisitions to drive growth.
RPG Life Sciences' subsidiary, RPG Active Pharma, will acquire the API business of Raghava Life Sciences for up to ₹135 Crore, expanding its manufacturing capabilities.
RPG Life Sciences' subsidiary will acquire the API and intermediates business of Raghava Life Sciences for Rs. 135 Crore via a slump sale.
Mr. Deepak Shukla has resigned as Chief Executive - API Business of RPG Life Sciences Limited, effective from the close of business hours on August 14, 2026.
RPG Life Sciences Limited completed the slump sale transfer of its Active Pharmaceuticals Ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma Limited.
RPG Life Sciences will invest up to ₹65.69 Crore in its wholly-owned subsidiary, RPG Active Pharma Limited, through a subscription to a rights issue of equity shares.
RPG Life Sciences is selling its API business to its wholly-owned subsidiary, RPG Active Pharma Limited, for a consideration of ₹33.55 Crore.
RPG Life Sciences' subsidiary, RPG Active Pharma, signed an investment agreement with ILSF and Vistaject. The deal involves an initial Rs. 243.33 crore capital infusion.
RPG Life Sciences will transfer its API business to subsidiary RPG Active Pharma and acquire Actis Generics. InvAscent will invest up to ₹700 Crore in the entity.
RPG Life Sciences will sell its API business for Rs. 33.55 Crore to its subsidiary and raise Rs. 243.33 Crore from investors in that subsidiary.
RPG Life Sciences reported robust Q1 FY27 results with 15.8% revenue growth and 17.0% PAT growth. Strategy focuses on building a specialty/chronic portfolio and expanding API and international footprint.
RPG Life Sciences reported Q1 FY27 Revenue of ₹195.7 Crore, a 15.8% increase, with EBITDA growing 17.9% to ₹48.0 Crore.
RPG Life Sciences Ltd reported revenue from operations of ₹195.7 Cr (+15.9% YoY) and net profit of ₹30.8 Cr (+17.1% YoY) for Q1 FY27.
Independent Director Ms. Zahabiya Khorakiwala ceased her tenure on July 26, 2026. Consequently, the company is reconstituting its Sustainability and Corporate Social Responsibility Committee.
RPG Life Sciences Ltd concluded its 19th AGM on July 23, 2026. All resolutions, including the dividend declaration, were passed with requisite majority.
RPG Life Sciences scheduled a board meeting for July 28, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
RPG Life Sciences Ltd filed its quarterly shareholding pattern. The filing indicates no change in promoter holdings for the period.
RPG Life Sciences partnered with Archerchem Healthcare to launch Naprosyn ES, a Naproxen‑Esomeprazole combo, across India. The product aims to address unmet NSAID therapy needs.
RPG Life Sciences convened its 19th Annual General Meeting for July 23, 2026. Key agenda items include declaring a Rs.24 per share dividend and adopting financial statements.
RPG Life Sciences Ltd has submitted its Annual Report for FY 2025-2026. The filing includes the Business Responsibility and Sustainability Report.
RPG Life Sciences cancels the inadvertently set record date for dividend eligibility. The corrected record date will be announced after the AGM.
RPG Life Sciences clarified that the recent surge in trading volume has no underlying unpublished event. The increase is attributed solely to market conditions.
RPG Life Sciences notified shareholders regarding the mandatory transfer of unclaimed dividends and shares to the IEPF. Shareholders must claim dues by September 01, 2026.
RPG Life Sciences reports 8.3% YoY revenue growth to ₹707.5 cr in FY26, driven by domestic formulations outperforming the market by 1.6x.
RPG Life Sciences Limited reported its FY26 results, with annual standalone total income of ₹733.06 Crore and net profit of ₹115.17 Crore. The Board recommended a dividend of ₹24 per share (300%). Additionally, Dr. Pratit Samdani was appointed as an Additional Independent Director for a five-year term.